Vaxxas Home

Vaxxas Nanopatch™ Technology

Vaccine Application System
Vaxxas Nanopatch Technology
Pages > About Vaxxas > Collaborative Partners

About Vaxxas

Collaborative Partners

Collaborative Partners

Pharma partnerships
Vaxxas is actively seeking partnerships with vaccine companies that have an interest in benefitting from the Nanopatch™ technology. We seek to work in partnership to optimise our delivery technology for the vaccines of interest and help our partners to deliver a cost effective, differentiated, high performance and safe product in the shortest timeframe possible. We believe that Nanopatch™ can:

  1. Enhance the therapeutic and market potential of existing vaccines, and
  2. Provide unprecedented immunogenic response to enable new, next generation vaccines.

Research partnerships
Professor Kendall at The University of Queensland ( has collaborated with research institutes worldwide including Oxford University, University of Washington, University of Melbourne and is also in close contact with PATH and the WHO.